The Technical Analyst
Alzamend Neuro, Inc. [ALZN]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Alzamend Neuro, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
-1.30% $0.700
America/New_York / 25 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 4.81 mill |
| EPS: | -1.820 |
| P/E: | -0.380 |
| Earnings Date: | Jul 03, 2024 |
| SharesOutstanding: | 6.87 mill |
| Avg Daily Volume: | 0.0569 mill |
| RATING 2024-04-25 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Neutral | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | 1/24 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | ||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.380 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.06x |
| Company: PE -0.380 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.791 (12.96%) $0.0907 |
| Date: 2024-04-26 |
| Expected Trading Range (DAY) |
|---|
|
$ 0.615 - 0.785 ( +/- 12.14%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-19 | Ault Milton C Iii | Buy | 1 000 | Common Stock |
| 2024-04-01 | Ault Milton C Iii | Buy | 334 | Common Stock |
| 2024-01-05 | Ault Milton C Iii | Buy | 2 000 | Common Stock |
| 2024-03-26 | Ault Milton C Iii | Buy | 780 000 | Warrants |
| 2024-03-26 | Ault Milton C Iii | Buy | 780 | Series B Convertible Preferred Stock |
| INSIDER POWER |
|---|
| -7.90 |
| Last 96 transactions |
| Buy: 11 786 230 | Sell: 5 921 131 |
Forecast:
16:00 - $0.700
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $0.700
Forecast 2: 16:00 - $0.700
Forecast 3: 16:00 - $0.700
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.700 (-1.30% ) |
| Volume | 0.0252 mill |
| Avg. Vol. | 0.0569 mill |
| % of Avg. Vol | 44.34 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ALZN
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
ALZN
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and AL002 that completed preclinical stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Latest Press Releases
2023-11-16 08:00:00 - Press Release
Alzamend Neuro Regains Compliance With Nasdaq's Minimum Bid Price Requirement
Atlanta--(business wire)---- $alzn #alzamend--alzamend neuro regains compliance with nasdaq's minimum bid price requirement.
2023-10-30 08:00:00 - Press Release
Alzamend Neuro Announces Reverse Stock Split
Atlanta--(business wire)---- $alzn #15_to_1_stock_reversal--alzamend neuro announces reverse stock split.
2023-04-04 06:30:00 - Press Release
Ault Alliance Announces Alzamend Neuro Has Initiated Its Phase I/iia Trial For Its Immunotherapy Vaccine (alzn002) To Treat Mild To Moderate Dementia Of The Alzheimer’s Type
Las vegas--(business wire)--ault alliance, inc. (nyse american: ault), a diversified holding company (“ault alliance” or the “company”), is proud to announce that alzamend neuro, inc. (nasdaq: alzn) (“alzamend”) has initiated its phase i/iia clinical trial for its immunotherapeutic vaccine (alzn002) to treat mild to moderate dementia of the alzheimer’s type. the company believes this marks a key milestone in clinical drug discovery and development, and ault alliance congratulates alzamend neuro on this achievement. the primary goal of this clinical trial is to determine the appropriate dose of alzn002 for treatment of patients with alzheimer’s in a larger phase iib efficacy and safety clinical trial, which alzamend expects to initiate within three months of receiving data from the initial trial...
2023-04-03 08:50:00 - Press Release
Alzamend Neuro Announces The Initiation Of A Phase I/iia Trial For Its Immunotherapy Vaccine (alzn002) To Treat Mild To Moderate Dementia Of The Alzheimer’s Type
Atlanta--(business wire)--alzamend neuro, inc. (nasdaq: alzn) (“alzamend”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of alzheimer’s disease (“alzheimer’s”), bipolar disorder, major depressive disorder (“mdd”) and post-traumatic stress disorder (“ptsd”), today announced the initiation of a phase i/iia clinical trial for its immunotherapy vaccine (alzn002) to treat mild to moderate dementia of the alzheimer’s type. the purpose of this trial is to assess the safety, tolerability, and efficacy of multiple ascending doses of alzn002 compared with that of placebo in 20-30 subjects with mild to moderate morbidity. the primary goal of this clinical trial is to determine an appropriate dose of alzn002 for treatment of patients with alzheimer’s in a larger phase iib efficacy and safety clinical trial, which alzamend expects to initiate within three months of receiving data from the initial trial...
2023-03-22 08:00:00 - Press Release
Alzamend Neuro Announces Completion Of Clinical Portion Of Phase Iia Multiple Ascending Dose Clinical Trial For Al001 Treatment Of Dementia Related To Alzheimer’s
Atlanta--(business wire)--alzamend neuro, inc. (nasdaq: alzn) (“alzamend”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of alzheimer’s disease (“alzheimer’s”), bipolar disorder, major depressive disorder (“mdd”) and post-traumatic stress disorder (“ptsd”), today announced the completion of the clinical portion of its phase iia multiple ascending dose (“mad”) study for dementia related to alzheimer’s. the mad study’s purpose was to evaluate the safety and tolerability of al001 under multiple-dose, steady-state conditions and determine the maximum tolerated dose in patients diagnosed with mild to moderate alzheimer’s and healthy subjects...
Latest News
2023-05-24 08:00:21 - InvestorPlace
3 Biotech Stocks That Could Turn $1,000 into $10,000 by 2024
Developing groundbreaking drugs and devices entails high costs, uncertain regulatory approval, and lucrative revenues. Those factors and more culminate to create a sector filled with dozens of biotech stocks that have 10X potential, or better.
2023-05-11 12:38:03 - InvestorPlace
3 Penny Stocks That Could Turn $1,000 into $10,000 in a Year
Turning $1,000 into $10,000 in a year in the stock market is undoubtedly a lofty goal. Make no bones about it, it's not particularly likely to happen.
2022-09-28 10:56:01 - PennyStocks
4 Alzheimer's Penny Stocks To Watch After Biogen Stock Explodes
Penny stocks to buy [or avoid] after Biogen Alzheimer's news. The post 4 Alzheimer's Penny Stocks To Watch After Biogen Stock Explodes appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-05-13 20:54:47 - PennyStocks
3 Penny Stocks to Add to Your Watchlist This Coming Week
Which penny stocks are you watching right now? The post 3 Penny Stocks to Add to Your Watchlist This Coming Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-01-04 19:45:00 - PennyStocks
Are These Penny Stocks Worth Buying Right Now?
Can penny stocks continue to show positive momentum in 2022? The post Are These Penny Stocks Worth Buying Right Now?
2021-12-19 18:30:00 - PennyStocks
Here's 3 Top Penny Stocks For Your January Watchlist
Can penny stocks continue to show momentum next year? The post Here's 3 Top Penny Stocks For Your January Watchlist appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2021-12-17 23:59:18 - Seeking Alpha
Alzamend: Biotech To Watch With 2 Drugs Targeting Multi-Billion Dollar Alzheimer's Market
Alzamend reported positive results from its phase 1 study using AL001 for the treatment of patients with Alzheimer's Disease.
2021-12-14 18:35:19 - The Motley Fool
Why Alzamend Neuro Stock Soared Today
2021-12-14 11:24:11 - PennyStocks
Penny Stocks To Buy According To 5 Analysts With 55%-246% Targets
5 penny stocks analysts say are a buy right now with hefty price targets. The post Penny Stocks To Buy According To 5 Analysts With 55%-246% Targets appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2021-12-12 10:52:31 - PennyStocks
Best Penny Stocks To Buy? 5 To Watch With Potential Catalysts This Week
5 penny stocks to watch this week The post Best Penny Stocks To Buy? 5 To Watch With Potential Catalysts This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.